Notification of Policy Revisions Effective July 18, 2023 (Posted May 16, 2023)
Medical Policy | Revision |
---|---|
Biomarker Testing for Autoimmune Rheumatic Disease AHS – G2022 Policy Effective 07/18/2023 Replacing ANA/ENA Testing AHS – G2022 | Reviewed by Avalon 1st Quarter 2023 CAB. Title changed to “Biomarker Testing for Autoimmune Rheumatic Disease”. Medical Director review 4/2023. Description, Policy Guidelines, and References updated Added once per lifetime limit related to testing for antinuclear antibodies (ANA) is allowed for individuals with a high clinical suspicion of autoimmune disease and repeat testing only if a significant change in symptoms occurs. Other coverage criteria updated for clarity. Billing/Coding section updated to add 81490. Notification given 5/16/2023 for effective date 7/18/2023. |
Blue Cross and Blue Shield of North Carolina does not discriminate on the basis of race, color, national origin, sex, age or disability in its health programs and activities. Learn more about our non-discrimination policy and no-cost services available to you.
Information in other languages: Español 中文 Tiếng Việt 한국어 Français العَرَبِيَّة Hmoob ру́сский Tagalog ગુજરાતી ភាសាខ្មែរ Deutsch हिन्दी ລາວ 日本語
© 2024 Blue Cross and Blue Shield of North Carolina. ®, SM Marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield plans. All other marks and names are property of their respective owners. Blue Cross and Blue Shield of North Carolina is an independent licensee of the Blue Cross and Blue Shield Association.